Medicilon Logo
|
search icon search icon language icon contact icon menu icon
Medicilon Logo
|
search icon close search icon language icon contact icon menu icon
CN
Contact Us
Close Button
Message
Back To Top
Online Message×
Click switch
Close Button
Medicilon's News information
News information

Join Medicilon at ELRIG Drug Discovery 2023 - Diverse Thinking, New Perspectives

2023-10-07
|
Page View:

4.pngELRIG Drug Discovery 2023 is only one week to go! Medicilon is excited to exhibit in the conference. This time, you can not only visit our table Stand H1, but also focus the speech “CHEMISTRY ENABLING DRUG DISCOVERY FROM START TO CLINIC” by our EVP and Head of IDSU, Dr. Xuedong Dai on October 19, 2023, 12:35-12:50.

The field of late-stage functionalization is rapidly evolving to meet the growing demand for expanding accessible chemical space, particularly from the area of drug discovery and development. Our presentation highlights the recent advancements in late-stage C-H bond functionalization (peripheral editing) and single-atom core modification (skeletal editing). These remarkable breakthroughs hold immense potential to enhance the efficiency of drug discovery process in the pharmaceutical industry.

We are happy to meet you in person to discuss how our services and capabilities would support your current research needs and expedite your drug discovery and development programs.

Date: 18-19 OCTOBER

Location: ACC LIVERPOOL EXHIBITION CENTRE

Medicilon Stand H1

2.jpg


About ELRIG

The European Laboratory Research & Innovation Group (ELRIG) is a leading European not-for-profit organization that exists to provide outstanding scientific content to the life science community. The foundation of the organisation is based on the use and application of automation, robotics and instrumentation in life science laboratories, but over time, ELRIG has evolved to respond to the needs of biopharma by developing scientific programmes that focus on cutting-edge research areas that have the potential to revolutionize drug discovery.

WHAT CAN I EXPECT FROM DRUG DISCOVERY 2023? 

This year’s scientific tracks cover a wide range of themes including ‘omics, personalised medicine and chemistry, all focused on bringing new therapies from the lab to the patient. With new tools being developed all the time, the exhibition hall is a great opportunity to find out about all the products and services you can use in your research.

Whether you’re involved in early drug discovery research or translating your promising therapy to the clinic, you’ll be sure to discover something that can help you at this year’s event.

Medicilon Drug Discovery Services

Medicilon drug discovery services include chemistry (synthetic chemistry, medicinal chemistry) and biology. In terms of chemistry, it can undertake multi-dimensional business such as custom synthesis, compound library construction, SAR compound synthesis and screening, compound structure and biological activity optimization.

The medicinal chemistry team deeply cross-integrates chemistry and biology into each project, and flexibly uses the powerful expertise of computational chemistry to aid the compound design process. At the same time, Medicilon extensively uses advanced drug discovery technology, including AI, PROTAC, ADC antibody drug conjugation technology, etc. Medicilon efficiently promotes customers' drug research and development projects, controls costs, and improves quality!

Medicilon Chemistry Research Services

With the rapid development of the global pharmaceutical market and the division of labor in the pharmaceutical industry, the chain is becoming more and more refined, making specialized outsourcing in the pharmaceutical industry an important strategic choice for pharmaceutical companies. In the early stages of new drug development, FTE (Full-time equivalent) is often used by drug discovery companies to synthesize the required structural fragments and/or potential candidate compounds to accelerate the drug screening process.Medicilon provides comprehensive chemistry research services covering all stages of your project requirements, and customers can cooperate with us through the FFS (Fee for Service) or FTE (Full-time Equivalent Service) models.

1.jpg

Global-leading New Molecule Types R&D Platform

2.png

PROTAC

PROTACs offer a fast and reversible chemical knock-down approach to control protein function in the cell. The impact of the PROTAC platform has changed the landscape of drug discovery and development. Medicilon’s PROTAC drug discovery technology platform covers many of the popular target protein ligands. We have established an extensive collection of bifunctional linkers. Together with our expanding E3 ubiquitin ligase binder library, we can efficiently synthesize highly active PROTAC bispecific small molecules, which have the potential to significantly facilitate the drug development process. In addition, Medicilon has established as well as improved the PROTAC biological screening and testing platform throughout the pre-clinical stages. Medicilon’s strong technical expertise and flexible service models allow individualized and customized projects ranging from sole chemical synthesis to in vitro and/or in vivo service, and to more comprehensive integrated package support. As of the end of 2022, Medicilon has successfully assisted in the clinical approval of 3 PROTAC drugs by NMPA and/or FDA.

Medicilon has:

• Know-how: > 6 years PROTACs experience

• Comprehensiveness: > 20 ongoing projects

• Talent: > 300 dedicated well-trained chemists

• Team: > 300 dedicated well-trained chemists

• Building Block: > 300 advanced linkers Available

• Scaffold: > 150 E3 ligands available including Cereblon, VHL, MDM2, IAP, etc.

ADC

Medicilon started ADC non-clinical research in 2014. As of the end of 2022, Medicilon has successfully assisted in the clinical approval of 13 ADC drugs by NMPA and/or FDA and has more than 10 ADC projects under development. Up to now, Medicilon has undertaken more than 100 major IND application biopharmaceutical projects, including monoclonal antibodies, double antibodies, polyclonal antibodies, ADCs, viral vaccines and fusion proteins.

Nucleic Acid Drug

Medicilon nucleic acid drug R&D platform provides an integrated and comprehensive solution that covers drug discovery, CMC and preclinical research services. Oriented with a rigorous scientific approach, an open-minded teamwork spirit and state-of-the-art equipment, our integrated solution will help clients and partners to fulfil their research and development mission for cutting-edge and innovative nucleic acid drugs. Our service platforms include nucleic acid drug discovery, screening and preclinical research services of pharmacology, DMPK and toxicity study for both pharmaceutical companies and academic research institutions. Attributed by its fast and intuitive design of base sequences, the development of nucleic acid drugs is featured with simple materials, convenient preparation processes and affordable production costs, which will greatly shorten the drug development cycle, making it possible to customize individual treatment plans. Hence, it offers a feasible solution for rare diseases and other problems currently plagued.

Antibody

With the development of antibody technology, antibody now presents a good development prospect. While major companies are deploying antibody product research and development, they also pay great attention to what needs to be paid attention to and considered in the biological analysis of antibody. Regulations and technical points. The Pharmaceutical Analysis Department of Medicilon Biotechnology is committed to tailoring Case by Case biological analysis methods for customers. As of the end of 2022, Medicilon has successfully assisted in the clinical approval of 17 monoclonal antibody drugs and 7 bispecific antibody drugs by NMPA, FDA, and TGA.

Peptide

In the research and development of peptide drugs, the many characteristics of peptides have caused difficulties and challenges in the analysis process. In the analysis of peptide biotechnology drugs, Medicilon Biotechnology Drug Analysis Department flexibly uses ELISA, ECL, TRFIA, CLIA, IF, IP, CoIP, qPCR, FACS, ELISpot, enzymology and other methods to support cutting-edge biology Drugs such as proteins, antibodies (monoclonal antibodies, bi- or multispecific antibodies, antibody fragments), ADCs, peptides, nucleic acids, vaccines and cell gene therapy and other drugs in the early development, preclinical and clinical stages of PK/TK/Immunogenicity (Total ADA& Nab)/Biomarker&Cytokine and other research evaluation.

mRNA Vaccine Bioanalysis Platform

Medicilon has provided comprehensive support and services for the safety and effectiveness evaluation of various new drugs and vaccines specifically the research of LNP-mRNA drugs and vaccines, accumulating rich experience. Hence we establish the bioanalysis platform for mRNA vaccines.

Cell & Gene Therapy

Cell & Gene therapy has developed rapidly in recent years, providing the possibility of curing many difficult-to-treat cancers. With the rapid development of gene transduction and gene modification technology, delivery vector system, cell culture technology and other fields, gene therapy has made a breakthrough, provide a better solution, concept and idea for intractable diseases (especially rare genetic diseases). Medicilon has established a one-stop research platform for the preclinical R&D of cell & gene immunotherapies, covering a variety of immunotherapy methods including CAR-T, TCR-T and CAR-NK. Using a wealth of animal models and a variety of advanced analysis techniques, comprehensively considering the characteristics of different research projects, Medicilon has completed multiple preclinical projects for clients worldwide.

#drugdiscovery #ELRIG #newmolecule

Share:
Return
Relevant newsRelevant news